Magnetic Resonance Perfusion Imaging of Prostate

Magn Reson Imaging Clin N Am. 2024 Feb;32(1):171-179. doi: 10.1016/j.mric.2023.09.007. Epub 2023 Oct 12.

Abstract

Magnetic resonance (MR) perfusion imaging, both with and without exogenous contrast agents, has the potential to assess tissue perfusion and vascularity in prostate cancer. Dynamic contrast-enhanced (DCE) MRI is an important element of the clinical non-invasive multiparametric MRI, which can be used to differentiate benign from malignant lesions, to stage tumors, and to monitor response to therapy. The arterial spin labeled (ASL) and intravoxel incoherent motion (IVIM) diffusion-weighted MRI have the advantage of quantitative perfusion measurements without the concerns of gadolinium-based contrast agent safety and retention issues. The adoption of these non-contrast techniques in clinical practice needs more research and clinical evaluation.

Keywords: Arterial spin labeled MRI; Dynamic contrast-enhanced (DCE) MRI; Intravoxel incoherent motion; Multiparametric MRI; Prostate cancer.

Publication types

  • Review

MeSH terms

  • Contrast Media
  • Diffusion Magnetic Resonance Imaging / methods
  • Humans
  • Magnetic Resonance Imaging* / methods
  • Magnetic Resonance Spectroscopy
  • Male
  • Perfusion
  • Perfusion Imaging
  • Prostate* / diagnostic imaging

Substances

  • Contrast Media